CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
- Gillison, Maura L
- Blumenschein, George
- Fayette, Jerome
- Guigay, Joel
- Colevas, A Dimitrios
- Licitra, Lisa
- Harrington, Kevin J
- Kasper, Stefan
- Vokes, Everett E
- Even, Caroline
- Worden, Francis
- Saba, Nabil F
- Iglesias Docampo, Lara Carmen
- Haddad, Robert
- Rordorf, Tamara
- Kiyota, Naomi
- Tahara, Makoto
- Monga, Manish
- Lynch, Mark
- Li, Li
- Ferris, Robert L
DOIAbstract
Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting. 2018
Add to ORKG